Clinical Safety of Chemotherapy for Elderly Cancer Patients Complicated with Hypertension

  • Qian, Ya-Dong (Deaprtment of Internal Medicine, Gao Gang People Hospital) ;
  • Xu, Xu (Deaprtment of Internal Medicine, Gao Gang People Hospital) ;
  • Wang, Lin (Deaprtment of Internal Medicine, Gao Gang People Hospital) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2014.12.18


Objective: To access the safety of chemotherapy for elderly cancer patients complicated with hypertension. Methods: Elderly cancer patients who were complicated with hypertension and treated by chemotherapy were recruited. All patients were treated by chemotherapy after an intervention on hypertension by psychotherapy, exercise guidance, salt regulation and nutrition support, therapy on hypertension, as well as prevention on hypertension associated complications. Results: In 68 eligible patients, two suspended chemotherapy because of adverse reactions and 4 because of disease progression. The remaining 62 patients completed chemotherapy smoothly based on good hypertension control. Conclusion: With effective control of blood pressure, chemotherapy for elderly cancer patients complicated with hypertension is generally safe.


Supported by : Nanjing science committee


  1. Cao Y, Tan A, Gao F, et al (2009). A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis, 24, 677-85.
  2. Choi KH, Park SM, Lee K, et al (2013). Prevalence, awareness, control, and treatment of hypertension and diabetes in Korean cancer survivors: a cross-sectional analysis of the fourth and fifth Korea national health and nutrition examination surveys. Asian Pac J Cancer Prev, 14, 7685-92.
  3. Daher IN, Yeh ET (2008). Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med, 5, 797-805.
  4. Havlik RJ, Yancik R, Long S, Ries L, Edwards B (1994). The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6.<2101::AID-CNCR2820741718>3.0.CO;2-M
  5. Izzedine H, Ederhy S, Goldwasser F, et al (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 20, 807-15.
  6. Jain M, Townsend RR (2007). Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep, 9, 320-8.
  7. Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JWW (1998). Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer, 21, 105-13.
  8. Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al (2004). Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax, 59, 602-7.
  9. Ko C, Chaudhry S (2002). The need for a multidisciplinary approach to cancer care. J Surg Res, 105, 53-7.
  10. Lopez-Encuentra A (2002). Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer, 35, 263-9.
  11. Pereira A, Garmendia ML, Alvarado ME, Albala C (2012). Hypertension and the risk of breast cancer in Chilean women: a case-control study. Asian Pac J Cancer Prev, 13, 5829-34.
  12. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL., Jr (2004). Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA, 291 2441-7.
  13. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens, 23, 460-8.
  14. Satariano WA, Ragland DR (1994). The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med, 120, 104-10.
  15. Smith AW, Reeve BB, Bellizzi KM, et al (2008). Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev, 29, 41-56.
  16. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005). Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 294, 1765-72.
  17. Townsend RR (2006). Hypertension and cancer chemotherapies. In: Mohler ER, Townsend RR, editors. Advanced Therapy in Hypertension and Vascular Disease. Toronto, Canada: BC Decker; 2006. pp. 502-7.
  18. Yancik R, Wesley MN, Ries LA, et al (1998). Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer, 82, 2123-34.<2123::AID-CNCR6>3.0.CO;2-W
  19. Yancik R, Wesley MN, Ries LAG, et al (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 285, 885-92.
  20. Yeh ETH (2006). Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med, 57, 485-98.

Cited by

  1. Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy vol.16, pp.2, 2015,
  2. Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer vol.16, pp.3, 2015,
  3. Adoptive Immunotherapy for Small Cell Lung Cancer by Expanded Activated Autologous Lymphocytes: a Retrospective Clinical Analysis vol.16, pp.4, 2015,
  4. Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis vol.16, pp.4, 2015,
  5. Inhibitory Effect of Curcumin on Invasion of Skin Squamous Cell Carcinoma A431 Cells vol.16, pp.7, 2015,
  6. Changes of Plasma Tumor Necrosis Factor α and C-Reactive Protein Levels in Patients with Hypertension Accompanied by Impaired Glucose Tolerance and their Clinical Significance vol.16, pp.8, 2015,
  7. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016,
  8. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016,